Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Global biosimilars market 360° synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Product trends
2.1.4 Application trends
2.1.5 Manufacturer trends
2.1.6 Technology trends
Chapter 3 Biosimilars Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Strong product pipeline
3.2.1.2 Rise in prevalence of chronic diseases across the globe
3.2.1.3 Expiry of blockbuster biologics
3.2.1.4 Cost-effectiveness of biosimilars
3.2.1.5 Recent biosimilar product approvals in major countries
3.2.2 Industry pitfalls & challenges
3.2.2.1 Availability of alternative medications
3.2.2.2 Regulatory uncertainty
3.2.2.3 High developmental costs
3.2.2.4 Complex manufacturing process
3.3 Growth potential analysis
3.3.1 By product
3.3.2 By application
3.3.3 By manufacturer
3.3.4 By technology
3.4 COVID- 19 impact analysis
3.5 Technology landscape
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Regulatory landscape
3.8.1 U.S.
3.8.2 Canada
3.8.3 Europe
3.8.4 India
3.8.5 Japan
3.8.6 South Korea
3.8.7 Australia
3.8.8 Singapore
3.9 Reimbursement landscape
3.9.1 U.S.
3.9.2 Europe
3.9.3 Canada
3.9.4 Australia
3.9.5 New Zealand
3.10 U.S. biosimilars insurance coverage, 2022
3.11 Biosimilar litigation landscape
3.12 Biosimilar product pipeline analysis
3.13 Biosimilars approval scenario, 2017-2022
3.13.1 U.S.
3.13.2 Canada
3.13.3 Europe
3.13.4 India
3.13.5 South Korea
3.13.6 Australia
3.13.7 New Zealand
3.13.8 Singapore
3.13.9 Malaysia
3.14 Biologics patent expiry scenario
3.15 Biosimilars industry evolution
3.16 Biosimilars factor analysis
3.16.1 Access
3.16.2 Regulations
3.16.3 Payer assessment and access
3.16.4 Physician acceptance
3.16.5 Patient acceptance
3.16.6 Number of biosimilar approvals
3.17 Biosimilars landscape - country analysis
3.17.1 U.S.
3.17.2 Europe
3.17.3 China
3.17.4 Japan
3.17.5 India
3.17.6 South Korea
3.18 International policies on use of biosimilar drugs
3.18.1 Interchangeability, Switching and Substitution
3.18.2 Supply Side Policies
3.18.3 Prescribing Incentives
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Strategic outlook matrix
4.5 Strategy dashboard, 2022
Chapter 5 Biosimilars Market Size and Forecast, By Product (USD Million)
5.1 Key trends, by product
5.2 Recombinant Non-Glycosylated Proteins
5.2.1 Human Growth Hormone
5.2.2 Granulocyte Colony-Stimulating Factor (Filgrastim)
5.2.3 Insulin
5.2.4 Interferon
5.2.4.1 Alfa
5.2.4.2 Beta
5.3 Recombinant Glycosylated Proteins
5.3.1 Erythropoietin
5.3.1.1 Alfa
5.3.1.2 Zeta
5.3.2 Monoclonal Antibodies
5.3.2.1 Infliximab
5.3.2.2 Rituximab
5.3.2.3 Adalimumab
5.3.2.4 Trastuzumab
5.3.2.5 Bevacizumab
5.3.2.6 Etanercept
5.3.3 Follitropin
5.3.3.1 Alfa
5.3.3.2 Beta
5.3.4 Low Molecular Weight Heparin (LMWHs)
Chapter 6 Biosimilars Market Size and Forecast, By Application (USD Million)
6.1 Key trends, by application
6.2 Hematology
6.2.1 Neutropenia
6.2.2 Anemia
6.2.3 Other hematology applications
6.3 Oncology
6.3.1 Lung cancer
6.3.2 Brain cancer
6.3.3 Breast cancer
6.3.4 Cervical cancer
6.3.5 Colorectal cancer
6.3.6 Leukemia
6.3.6.1 Non-Hodgkin Lymphoma (NHL)
6.3.6.2 Chronic Lymphocytic Leukemia (CLL)
6.3.6.3 Others
6.3.7 Other cancers
6.4 Autoimmune Disease
6.4.1 Arthritis
6.4.1.1 Rheumatoid arthritis
6.4.1.2 Psoriatic arthritis
6.4.1.3 Juvenile arthritis
6.4.1.4 Ankylosing spondylitis
6.4.1.5 Other arthritis
6.4.2 Inflammatory Bowel Disease (IBD)
6.4.2.1 Ulcerative Colitis
6.4.2.2 Crohn's disease
6.4.2.3 Other IBD
6.4.3 Psoriasis
6.4.4 Other autoimmune diseases
6.5 Growth hormone deficiency
6.6 Diabetes
6.7 Other applications
Chapter 7 Biosimilars Market Size and Forecast, By Manufacturer (USD Million)
7.1 Key trends, by manufacturer
7.2 Contract research and manufacturing services
7.3 In-house
Chapter 8 Biosimilars Market Size and Forecast, By Technology (USD Million)
8.1 Key trends, by technology
8.2 Recombinant DNA Technology (rDNA technology)
8.3 Monoclonal Antibodies (MAb) Technology
Chapter 9 Biosimilars Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Turkey
9.3.7 Austria
9.3.8 Belgium
9.3.9 Bulgaria
9.3.10 Czech Republic
9.3.11 Denmark
9.3.12 Finland
9.3.13 Greece
9.3.14 Hungary
9.3.15 Ireland
9.3.16 Netherlands
9.3.17 Norway
9.3.18 Romania
9.3.19 Slovakia
9.3.20 Slovenia
9.3.21 Sweden
9.3.22 Switzerland
9.3.23 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 New Zealand
9.4.7 Singapore
9.4.8 Malaysia
9.4.9 Rest of Asia Pacific
9.5 Latin America
9.6 Middle East & Africa
Chapter 10 Company Profiles
10.1 Biocon Ltd.
10.2 Sandoz
10.3 Viatris
10.4 Bio-Thera Solutions
10.5 Pfizer
10.6 Dr. Reddy’s Laboratories
10.7 Amgen Inc.
10.8 Teva Pharmaceuticals
10.9 Fresenius Kabi
10.10 Coherus Biosciences
10.11 Apobiologix
10.12 Biocad
10.13 Intas Pharma
10.14 Reliance Life Sciences
10.15 Celltrion
10.16 Zydus Cadila
10.17 Lupin Pharma
10.18 Samsung Bioepis
